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Involvement of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) in kidney physiology has been
explored recently. Synthetic PPARγ ligands can ameliorate the diabetic kidney disease through diﬀerent mechanisms, involving
inhibition of mesangial cell growth, reduction of mesangial matrix, and cytokine production of glomerular cells as well as
promoting endothelial cell survival within the kidney glomeruli. Activation of PPARγ has additional proﬁbrotic consequences,
which can contribute to wound healing in diabetic glomerulonephritis. Beside many beneﬁcial eﬀects, PPARγ activation, however,
can lead to severe water retention, a common side eﬀect of thiazolidinedione therapy. This unwanted eﬀect is due to the activation
of PPARγ in the mesonephric distal collecting system, where PPARγ positively regulates sodium and water resorbtion leading to
the expansion of interstitial ﬂuid volume. Recent studies indicate that PPARγ is also involved in the normal kidney development,
renal lipid metabolism, and activation of the renin-angiotensin system. In this paper, we give a synopsis of the current knowledge
on PPARγ functions in kidney phyisology and pathophysiology.
Copyright © 2008 ´ E. Kiss-T´ oth and T. R˝ oszer. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The nuclear receptor peroxisome proliferator-activated
receptor gamma (PPARγ) regulates transcription of various
genes involved in lipid uptake, fatty acid metabolism, and
glucosehomeostasis[1],therefore,themodulationofPPARγ
action is of intense interests in the medication of insulin
resistance and related metabolic disorders [2–7]. Pharma-
cological activation of PPARγ facilitates the glucose and
free fatty acid ﬂux from striated muscle ﬁbers to adipocytes
and reduces liver gluconeogenesis by which PPARγ exerts
antidiabeticbeneﬁts[1,5,6].PPARγ signalingcanalsoinﬂu-
ence the expression of insulin-dependent glucose transport
(GLUT) proteins [8], and can induce the production of
hormone-like substances in adipose cells (e.g., resistin and
adipokines) promoting insulin responsiveness [1]. Recent
studies indicate that impaired insulin sensitivity of skeletal
muscle and white adipose tissue can be a consequence of a
chronicsubclinicalinﬂammation[2–6].ActivationofPPARγ
in macrophages has anti-inﬂammatory eﬀects, by which
PPARγ ligands can reduce the local low-grade inﬂammation
and consequent insulin resistance of muscle and adipose
tissues [5, 6]. Thiazolidinediones (TZDs), synthetic ligands
of PPARγ are clinically proven insulin sensitizers with
antiinﬂammatory beneﬁts. Nowadays, TZD therapy is a
widely used medication strategy of type 2 diabetes and
related diseases [5, 6].
Beside beneﬁcial eﬀects of TZD therapy in insulin
resistance, edema and water retention also frequently occurs
as secondary eﬀects of PPARγ activation [9, 10]. The
understanding of TZD side eﬀects highly facilitated the basic
researchonPPARγ andkidneyphysiology.Asaresult,several
fundamental ﬁndings on the involvement of PPARγ in ﬂuid
homeostasis have been explored in the recent years [1, 10–
18]. These ﬁndings indicate that PPARγ is involved in the
regulation of sodium and water resorbtion of the distal
collecting ducts of the kidney which explains the unwanted
TZDeﬀectsoninterstitialﬂuidvolumeregulation[9,17,18].
Due to the anti-inﬂammatory roles of PPARγ activation, the
receptorisinvolvedintheattenuationofglomerulonephritis,
which is also a potent therapeutic value of TZDs [10–16].
Many other roles are also attributed to PPARγ in normal
kidney development, lipid metabolism, and endocrine func-
tions [19]. In this paper, we give a synopsis of PPARγ actions2 PPAR Research
as well as the PPARγ-independent eﬀects of synthetic PPARγ
ligands in kidney phyisology and pathophysiology.
2. PPARγ IN THE FILTRATION UNITS OF THE KIDNEY
2.1. Diabetickidneydiseaseiscoupledtoimpaired
mesangialcellfunctions
In the latest years, several articles explored the conneciton
of PPARγ and the impaired function of the kidney ﬁltration
units in diabetic kidney disease [10, 12–15]. More than
30% of patients with juvenile or maturity onset diabetes
mellitus develop clinically evident diabetic glomerulopathy
within 10–20 years of the diabetes onset [16, 20]. After years
of poor glycemic control, the structure of the glomerular
walls get scarred and permeability changes can develop
which are core features of the diabetic glomerulosclerosis
or glomerulonephritis [20]. The disease is characterized by
the strong accumulation of extracellular matrix proteins
(Figure 1)anddepositionoftypeIVcollagenintheglomeru-
lar mesangium leading to the expansion of mesangial matrix
and glomerular size [10, 12–16, 21, 22]. Elevated glomerular
size can manifest in kidney hypertrophy [20]. Alterations of
the glomerular morphology lead to ﬂuid ﬁltration deﬁcits,
albuminuria, glucosuria, and ﬁnally reduction of glomerular
ﬁltration [21–30].
Glomerular mesangial cells have a central role in the
development of diabetic glomerulonephritis (Figure 1(b)),
since these cells can overproduce the extracellular matrix
proteinsoftheglomerularmesangiuminresponsetochronic
hyperglycemia [11–13, 21].
2.2. EffectsofPPARγ activationinmesangialcells
Activation of PPARγ as well as PPARα in mesangial cells
can attenuate the overproduction of the mesangial matrix
(Figure 1(f)), as it has been described in animal models of
diabetic nephropathy [21, 22]. Diabetes in apolipoprotein-
E (ApoE)-deﬁcient mice is associated with a signiﬁcant
accumulation of extracellular matrix proteins and increased
immunostaining for collagen IV in the glomerular com-
partments (Figures 1(d), 1(e)). Treatment with rosiglitazone
results in a signiﬁcant reduction in collagen IV deposition
[21]. In Otsuka Long-Evans Tokushima Fatty (OLETF),
type 2 diabetic rats glomerular hypertrophy correlates well
with the expression of large quantities of the Bcl-2 protein,
an apoptosis-suppressing molecule in the mesangial cells
[22]. This ﬁnding suggests that persistent proliferation and
prolonged survival of the mesangial cells can also contribute
to the supernormal matrix secretion in glomerulopathy.
The gene encoding Bcl-2 has a PPAR response element
by which PPARγ can increase Bcl-2 mRNA transcription.
However, some reports have indicated that TZD treatment
can decrease the level of Bcl-2 and induce apoptosis inde-
pendently of PPARγ [22].
TZDscannotonlyreduceglomerularcross-sectionalarea
and the mesangial matrix size as well as collagen IV synthesis
but also enhance the tumor growth factor beta-1 (TGF-β1)
positive staining areas in the kidney of OLETF rats [22].
TGF-β seems to be a central molecule in the PPAR agonist
action [10, 12, 22]. This growth factor activates several
intracellular signal transduction systems involved in the reg-
ulation of the extracellular matrix biosynthesis (Figure 1(f)),
including mitogen-activated protein kinases (MAPKs), the
extracellularsignal-regulatedkinases(ERKs),thec-junNH2-
terminal kinases, diacylglycerol/protein kinase C extracellu-
lar signal-regulated kinase pathway, and the p38 MAPK [23–
30]. PPARγ agonists besides their anti-inﬂammatory eﬀect
can inhibit TGF-β expression leading to a repression in
glomerular proliferation [16, 22, 30]. PPARγ also has a direct
eﬀect on key extracellular matrix regulators as plasminogen
activator inhibitor-1 (PAI-1). PAI-1 is a member of the
serine protease inhibitor superfamily and it can inhibit
proteolysis of the extracellular matrix, leading to matrix
accumulationandsclerosis.PPARγ agonistsmayinhibitPAI-
1 transcription by antagonizing the activities of activator
protein-1 (AP-1) and nuclear factor κB[ 23–31].
T h ep r e s e n c eo fT G F - β1 in the mesangial cells refers to
a mechanism by which high-glucose milieu induces inﬂam-
matory and proﬁbrotic cytokine production in glomeru-
lar cells (Figure 1(f)). In diabetic nephropathy, mesangial
cells as well as podocytes and interstitial cells can secrete
monocyte chemoattractant protein-1 (MCP-1) and TGF-
β1 which may initiate macrophage inﬁltration into the
kidney [10, 12–15]. The number of inﬁltrated machrophages
is being increased both in the glomeruli and the renal
interstitium with the development of diabetic kidney disease
in OLETF rats. TZDs have an anti-inﬂammatory eﬀect
in the peripheral tissues, therefore treatment with piogli-
tazone or rosiglitazone decreases macrophage inﬁltration
of the kidney [19, 22, 30]. MCP-1 can also inﬂuence
the alternative macrophage activation. Alternatively acti-
v a t e dm a c r o p h a g er e l e a s ef a c t o r ss u c ha sI L - 1 r a / I L - 1 F 3 ,
IL-10, and TGF-β [31–33]. TGF-β functions indirectly to
promote extracellular matrix building by inducing nearby
kidney ﬁbroblasts to produce matrix components [34].
The alternatively activated macrophages themselves produce
extracellular matrix components, as ﬁbronectin and a cross-
linking enzyme transglutaminase (Figure 1(f)), as well as
osteopontin, which is involved in cell adhesion to the matrix
[32,35].Themoleculessecretedbythealternativelyactivated
macrophages can promote wound repair due to their anti-
inﬂammatory, ﬁbrotic, proliferative, and angiogenic activi-
ties [32–35].
2.3. RoleofPPARγ inpodocytesand
capillariesinglomerulonephritis
Podocyte injury is also among the primary events in early
developmentoftheglomerulosclerosis[33,36].Adecreasein
podocyte number in type 2 diabetic Pima Indians correlates
closely with those patients who have microalbuminuria, the
earliest manifestation of diabetic nephropathy [37]. High-
glucose treatment or the epithelial cell toxin puromycin
aminonucleosid (PAN) supplementation induces podocyte
injury and PPARγ upregulation in podocyte culture [37].
This increase of PPARγ is counterregulatory and might
promotepodocytehealingandrepair.Pioglitazonetreatment´ E. Kiss-T´ oth and T. R˝ oszer 3
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Figure 1: Roles of PPARγ in the ﬁltration units of the kidney. The kidney capsules (a) contain the glomerular capillaries covered with
podocytes (pc). In the wall of the aﬀerent arterioles, modiﬁed smooth muscle cells form the juxtaglomerular system (jg). The ﬁltrated urine
is guided to the proximal tubules (pt). The distal tubules (dt) can return to the cortical kidney capsules and their epithelial layers serve
as a chemosensory region, the macula densa (labeled with red). (b) PPARγ activation aﬀects either podocyte (pc), mesangial cell (ms), or
endothel cell (en) functions. (c) Periodic acid-Schiﬀ (PAS) stained sections of a normal kidney capsule in mouse. (d) Glomerulonephritis in
high-fat diet fed mouse and (e) type 2 diabetic (db/db) mouse, showing intensive PAS staining of the expanded mesangial matrix, thickening
of glomerular walls, and enlargement of kidney capsules. (f) Summary of PPARγ-mediated cellular events in mesangial cells, podocytes,
kidney macrophages, and glomerular endothel cells.
of podocytes can inhibit expression or phosphorylation of
cell proliferation and antiapoptotic proteins (e.g., p27Kip1,
p42 MAPK, Bcl-2) which can be one major molecular
mechanism behind the therapeutic potential of TZDs on
high glucose-induced hypertrophy of podocytes [22, 23].
Microangiopathy of glomerular capillaries is also a
hallmark of the diabetic nephropathy [10, 12–15, 33].
Endothelial growth and survival are regulated by two factors,
vascular endothelial growth factor (VEGF) and angiopro-
tein which are also expressed by podocytes (Figure 1(f)).
PPARγ agonists can protect glomerular capillaries against
injury both by increasing podocyte VEGF expression and
by decreasing Aglp4 [38]. TZDs, therefore, can prevent
angiopathy of the capillaries in the glomeruli, one causing
event of progressive kidney disease.
3. PPARγ IN THE DISTAL COLLECTING SYSTEM
3.1. ExpressionofPPARγ inthenephronducts
Under physiological conditions, PPARγ is dominantly
expressed in the collecting system of the mammalian urinary
tract, including connective renal tubules and collecting
ducts (Figure 2(a)). PPARγ is abundant in the inner renal
medulla (Figures 2(b), 2(c)) and localized to the epithe-
lial layer starting from medullary collecting ducts to the
urothelium of the ureter and the bladder [39–41]. PPARγ
also occurs in renal medullary interstitial cells [39]. The
PPARγ partner RXRα has a complimentary distribution
in the collecting ducts [42]. The connective tubules and
collectiveductsarepartsofthedistalcollectingsystem,where
hormone-regulated ion exchange and water resorbtion takes4 PPAR Research
place and provides the balance of interstitial ﬂuid volume
(Figure 2(e)). If aldosterone is present, sodium is resorbed
and potassium is secreted. Sodium transport is followed
by passive water resorbtion, therefore, this mechanism
regulates the total electrolite and water volume in the body
[43]. The epithelium of the collecting ducts is responsive
to antidiuretic hormone. If the hormone is present, the
epithelia becomes permeable to water. The distal collecting
system is, therefore, a major site of ﬂuid volume regula-
tion.
3.2. Embryologyandphylogenetichomologiesof
PPARγ expressingcollectingducts
In mammals, the development of the kidney collecting
system diﬀers from the other excretory parts of the kidney
[44]. Collecting ducts and tubules are formed by the ureteric
bud, which is an outgrowth of the dorsomedial wall of
the mesonephric duct. The proliferating mesonephric bud
penetrates the developing metanephric tissues and dilates
forming the primitive renal pelvis and calyces. The further
subdivisions of the calyces form the presumptive collect-
ing ducts [44]. According to the recent literature, PPARγ
expression is mainly conﬁned to the collecting system of
the kidney [39, 41, 45–55], which has a mesonephric origin
(Figure 2(a)). A lower expression of PPARγ1 in the proximal
tubules, which are derived from the metanephric tissue, has
been indicated in the rat kidney [56] while in mesangial cells
and podocytes of the kidney capsules PPARγ is upregulated
onlyunderpathologicalconditionsaschronichyperglycemia
or glomerulonephritis [10, 12–15]. The distribution pattern
of PPARγ suggests that PPARγ may have been coupled to the
mesonpehros in the vertebrate phylogeny. Supporting this
possibility, the kidney of teleost ﬁshes, which is a functioning
mesonephros and a phylogenic homolog of the mammalian
collecting system, contains all of the three PPAR isoforms
[57–59]. Like their mammalian homologs, ﬁsh PPARs bind
to a variety of natural PPAR response elements (PPREs)
present in the promoters of mammalian or piscine genes.
3.3. RoleofPPARγ inthebalanceofﬂuidhomeostasis
As its distribution pattern suggests, the clinically most
relevant function of PPARγ is the modulation of electrolyte
and water resorbtion [17, 18, 41, 60]. Edema and ﬂuid
retention are common and serious side eﬀects of TZD
therapy, which are due to supernormal sodium resorbtion
and consequent interstitial ﬂuid volume expansion [9, 32].
Since PPARγ is a signiﬁcant target for TZDs and it is
predominantly expressed in the collecting ducts, critical sites
for the control of ﬂuid metabolism, its possible involvement
in ﬂuid metabolism has been recently elucidated. PPARγ
activation can modulate sodium resorbtion through the
stimulation of epthelial sodium channels and the Na+/K+-
ATPase system [41, 60]. Additionally, TZDs can ditsurb
the renin-angiotensin-aldosterone system also (Figure 2(e)).
In human collecting duct cell culture PPARγ activation
enhances the expression of cell surface epithelial sodium
channels which can facilitate the sodium resorbtion ability
of the tubular cells [41] .T h er o l eo fP P A R γ in the regulation
of sodium resorbtion has been also conﬁrmed by studies
carried out on mice with collecting duct-speciﬁc ablation of
PPARγ [17, 18]. These studies show a critical role for PPARγ
in systemic ﬂuid retention through the regulation of renal
sodiumtransport,andthattheadverseeﬀectsofTZDinﬂuid
metabolism are indeed PPARγ-dependent. A gene encoding
for the gamma subunit of the epithelial sodium channel has
been identiﬁed as a critical PPARγ target gene in the control
of electrolyte and water resorbtion of the collecting ducts
(Figure 2(e)).
3.4. Proliferationandmetabolismof
kidneyepitheliaandeffectsofPPARγ
PPARγ has some additional functions in the collecting
system of the kideny. During embryogenesis, the expression
of PPARγ in urothelium [41, 46, 55] suggests its possible
involvement in the urothelial proliferation and diﬀerentia-
tion. In cultured rat kidney epithelial cells, both troglitazone
and 15d-PGJ2 signiﬁcantly inhibit cell proliferation and
dramatically alter cell shape by induction of cell process
formation [19, 41]. TZDs or PPARγ overexpression induces
the Klotho gene expression in mouse kidneys and renal
epithelial cell culture promoting insulin sensitivity and
reducing cellular aging [46].
The PPARγ ligand TZDs alter not only cellular growth
and survival but also metabolic processes of the kid-
ney collecting duct epithelia including carbohydrate, lipid
metabolism, and albumine transport [19, 47]. TZDs can
activate PPARγ- r e g u l a t e dg e n e sa sw e l la sP - E R Ka n dA M P -
activatedproteinkinasepathwayswhichmodulategluconeo-
genesis, cellular acidosis, glutamine metabolism, and ammo-
niagenesis of porcine tubular cells [19]. It is possible that
modulationofkidneycarbohydratemetabolismbyTZDshas
a beneﬁcial role in the glycemic control [19]. Interestingly
some in vitro studies with kidney epithelial cells of the
opossum have revealed that TZD aﬀects protein handling
of tubular epithelia also [47]. Rosiglitazone, ciglitazone, and
troglitazone can inhibit the uptake of FITC-labeled albumin
by tubular epithelial cells in a dose-dependent manner
without any cytotoxic eﬀect. Unexpectedly, in tubular cells
overexpressing PPARγ or in cells treated with the PPARγ
antagonist GW9662, albumin handling cannot be aﬀected.
Similarly, the PPARγ ligand 15d-PGJ2, which is structurally
unrelated to TZDs, has no eﬀect on albumin uptake [47].
Albumin handling of tubular cells can be, therefore, aﬀected
by TZDs independently from PPARγ.E ﬀects of TZDs on
tubular protein uptake, however, can be physiologically
less relevant than the beneﬁts of TZD administration on
glomerular functions which conseqeuntly reduce albumin-
uria.
PPARγ is also involved in the renal lipid metabolism
(Figures 2(d), 2(e)). Abnormal renal lipid synthesis plays a
role in the pathogenesis of diabetic nepropathy [48]. Renal
lipid deposits in glomerulosclerosis have been mentioned
even in the ﬁrst description of the diabetic kidney alterations
by Kimmelstiel and Wilson in 1936 [49]. Lipid deposits
are present in the kidney of diabetic humans as well as´ E. Kiss-T´ oth and T. R˝ oszer 5
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Figure 2: Roles of PPARγ in the collecting system of the kidney. (a) Expression of PPARγ is conﬁned to the distal collecting system (labeled
with green) including connective tubules (cn) and collective ducts (ct). (b) Hematoxylin and esoin stained cross-sections of the kidney
medulla showing numerous collective ducts (ct). (c) Fluorescent PPARγ immunostaining in the same region of the kidney. (d) Oil red-
O stained sections of the distal tubules (dt) showing severe lipid accumulation in type 2 diabetic (db/db) mice. (e) Summary of PPARγ
functions in the collective system.
of diabetes model rodents [48–55, 61, 62]. In diabetic
animals upregulation of kidney SREBP-1, the key enzyme
of fatty acid synthesis can lead to the renal accumula-
tion of lipids as well as mesangial matrix expansion and
kidney hypertrophy [51, 52]. Elevated levels of plasma
lipids also can contribute to renal fat deposition and
facilitate the development of glomerulosclerosis [53]. High
glucose concentration can also increase SREBP-1 expression
in cultured rat mesangial cells, suggesting that impaired
glycemic control can disturb renal lipid metabolism through
altered SREBP-1 gene expression, which is regulated by
PPARγ [51]. It is possible that the transcriptional activity
of PPARγ in the duct cells is upregulated by insulin
and C-protein, a protein fragment of proinsulin [54].
Both insulin and C-peptide can induce a concentration-
dependentactivationofPPARγ andbothagentscanaugment
the TZD-stimulated PPARγ activity giving the possibility
that hyperinsulinemia in type 2 diabetes can augment
PPARγ as well as PPARγ-regulated SREBP-1 gene func-
tions.
Renal lipid accumulation, however, not only is a conse-
quence of the hyperglycemia or dyslipidemia but also can
predispose or provoke glomerulonephritis. Recent in vitro
studies suggest that low-density lipoproteins and very low-
density lipoproteins induce upregulation of growth factors,
TGF-β, and matrix proteins in cultured renal mesangial
and tubular cells [55, 61]. This direct eﬀect of lipids on
gene expression of kidney cells can initiate the development
of mesangial matrix expansion which is a hallmark of
glomerulonephritic syndrome. In mice with upregulated
SREBP-1 expression, the signs of glomerulonephritis as
albuminuria, renal cholesterol, and triglyceride deposits
occur without changes in glucose homeostasis or serum
lipid levels [51]. In these SREBP-1 transgenic mice, the
elevated renal lipid content is coupled with increased TGF-
β and vascular endothelial growth factor (VEGF) expression
[51]. VEGF plays a pivotal role in the pathogenesis of
glomerulosclerosis [63]. PPARγ haploinsuﬃciency as well
as Pro12Ala (P12A) allele polymorphism of PPARγ has a
protective role in the development of diabetic nephropathy
[64]. In mice with heterozygous PPARγ mutation, high-fat
diet results in a less severe nephropathy and lipid depositions
than in wild type animals [45].
4. PPARγ FUNCTION IN THE
JUXTAGLOMERULAR APPARATUS
Kidney is not only an excretory organ but also serves
endocrine functions by the secretion of renin, a 37kDa
protein hormone produced by the juxtaglomerular cells.
Juxtaglomerular cells are modiﬁed smooth muscle cells in
the media of the aﬀerent arteriole adjacent to the renal6 PPAR Research
capsule (Figure 1(a)). Renin acts on a plasma protein called
angiotensinogen, producing an inactive decapeptide, the
angiotensin I. This substance as a result of the action of a
converting enzyme present in high concentration in lung
endothelialcells,becominganoctapeptidecalledangiotensin
II.AngiotensinIIenhancesthesecretionofaldosteroneinthe
adrenal gland [65, 66]. The main targets of aldosterone are
the distal tubules, where it can regulate sodium reabsorption
(Figure 2(e)).
Human renin gene enhancer is modulated by PPARγ
activation [67, 68]. In human renin-producing cell line
CaLu-6, endogenous or pharmacological PPARγ agonists
(unsaturated fatty acids and TZDs) can stimulate renin
mRNA transcription [67, 68].
Although renin production is facilitated by PPARγ
activation, the hypertensive eﬀects of angiotensin II can
be attenuated by TZDs [69–71]. In addition to its role
in controlling water and salt homeostasis, the inhibition
of the renin-angiotensin system reduces the incidence of
type 2 diabetes in patients with hypertension or congestive
heart failure and also reduces the risk of nephropathy in
diabetic patients [71]. The mechanisms underlying these
protective eﬀects appear to be complex and may involve
an improvement of both insulin sensitivity and insulin
secretion. Recent works suggest that aldosterone and min-
eralocorticoid receptors regulate PPARγ expression [72, 73].
Aldosterone as well as angiotensin receptor blockers appear
to induce PPARγ activity in the adipose tissue, which could
explain the protective eﬀect of the renin-angiotensin system
inhibition against the development of type 2 diabetes [71].
It is unlikely, however, that the favorable eﬀects of TZDs on
diabetic nephropathy would be related to a dierct eﬀect on
the renin-angiotensin system [74].
5. CYTOTOXIC EFFECTS OF PPARγ LIGANDS ON
TUBULAR EPITHELIAL CELLS
Synthetic PPARγ ligands are widely used drugs for the
treatment of insulin resistance. There is an evidence that
these drugs have beneﬁcial eﬀects on the improvement of
metabolic parameters as proteinuria in type 2 diabetes,
however, some severe metabolic secondary eﬀects have been
recognized [75–77].
Increasing number of synthetic PPARγ ligands is com-
mercially available today (e.g., troglitazone, rosiglitazone,
pioglitazone, ciglitazone, muraglitazar) for treatment of type
2 diabetes complications. Many reports have described the
side eﬀects of them including antiproliferative and apoptotic
actions in cultures of renal proximal tubular cells [78],
mesangial cells [79], and interstitial ﬁbroblasts [80]. Ciglita-
zone has a direct necrotic eﬀect on renal proximal tubular
cells at a concentration range similar to its therapeutical
plasma levels. Interestingly, these cytotoxic eﬀects are not
universal for all PPARγ agonists because pioglitazone is not
cytotoxic in the same cell lines [81]. Although renoprotective
eﬀects of dual PPARα and PPARγ activation have been
reported in type 2 diabetic animals [82], muraglitazar (a
PPARα/γ dual agonist) can induce multifocal urothelial
necrosis and proliferation in young male rats which is
thought to be provoked by muraglitazar-associated changes
in urine composition [83] .
6. SUMMARY
PPARγ agonists have many beneﬁcial eﬀects combined
with their independent antiatherosclerotic actions and their
important eﬀects on dyslipidemia and insulin resistance in
themedicationofkidneydiseasecoupledtodiabetes[10,12–
15,21,82].ActivationofPPARγ attenuatesdiabeticglomeru-
lonephritis due to its anti-inﬂammatory and proﬁbrotic
eﬀects [32–35]. PPARγ and PPARα have similar antidia-
betic and renoprotective eﬀects, therefore administration of
PPARα or PPARα/γ dual agonists may be also useful for
the prevention of kidney complications of type 1 as well as
t y p e2d i a b e t e sm e l l i t u s[ 13, 21, 82]. On the other hand,
PPARγ signalingcanfacilitatelipidaccumulationorinducea
direct necrotic cell death of tubular epithelial cells, therefore
synthetic PPARγ ligands, especially TZDs should be used
with a great foresight in the medication of insulin-resistant
diabetes mellitus [1, 48–54].
The most recently discovered role of PPARγ in the
positive regulation of salt and water resorbtion have eluci-
dated the pathomechanism of water retention and edema in
patients treated with TZDs, the widely used PPARγ agonists
[17,18]. Edema and ﬂuid retention canbe fatalside eﬀectsof
TZDs, which can be attenuated by the combination of TZD
therapy with diuretics [9]. The selective PPAR modulator
(SPPARM) approach has also been proposed as a method to
avoid unwanted complications of PPARγ ligands [9].
Some comparative data suggest that PPARγ is coupled to
the mesonephric parts of the vertebrate kidney, therefore the
involvement of PPARγ in the intesrtitial ﬂuid volume regu-
lation can be an ancient and evolutionarily conserved role
[56–58]. Some other components of renal PPARγ activation,
including the function of PPARγ in the moduation of renal
endocrine functions, are still undeﬁned [67, 74] indicating
the timeliness of future research in the ﬁeld of PPARγ and
kidney physiology.
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